Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ChemoCentryx, Inc.
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
ChemoCentryx gets US approval of Tavneos for ANCA vasculitis, which it says may gradually ramp up to a blockbuster revenue opportunity. Current steroid-heavy standard of care has many drawbacks.
Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.
- Drug Discovery Tools